Ibrutinib Monotherapy Produces Long-Term Disease Control in Previously Treated Waldenstrom's Macroglobulinemia. Final Report of the Pivotal Trial (Nct01614821).

Hematological Oncology - United Kingdom
doi 10.1002/hon.141_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248

Clinical Cancer Research
Cancer ResearchOncology
2007English

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

Clinical Cancer Research
Cancer ResearchOncology
2017English

OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) in Previously-Treated Malignant Mesothelioma (MM): Final Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Long-Term Follow-Up of the RESONATE™ Phase 3 Trial of Ibrutinib Versus Ofatumumab

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom Macroglobulinemia

Clinical Cancer Research
Cancer ResearchOncology
2012English

Ofatumumab Monotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Final Results From a Pivotal Study

Haematologica
Hematology
2015English

PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

IgM Myeloma: An IgM Gammopathy Distinct From Waldenstrom's Macroglobulinemia

Hematology
Hematology
2001English

Diagnostic Tools of Waldenström’s Macroglobulinemia – Best Possibilities for Non-Invasive and Long-Term Disease Monitoring

Klinicka Onkologie
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy